BioSante receives two further US patents covering 2A/Furin technology to save expressing proteins
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the proceeds of two US latest patents directed to its 2A/Furin technology in place of expressing proteins. The victory issued US transparent, US Stroke. No., 7,709,224, covers methods suited for manufacturing recombinant antibodies. Nearby incorporating our 2A/Furin technology into antibody-expression in viral vectors it is practicable to at full speed produce steadfast, exorbitant producing antibody cubicle lines. The in the wake cubicle lines may greatly downgrade the point and slash the fetch of commercial antibody effort. The promote issued US trade mark, US Appropriate. No. 7,714,199 covers additional adeno-associated virus (AAV) vectors containing the 2A/furin technology and methods in search expressing antibodies in vivo using these vectors and builds on already issued patents covering vectors and methods in support of producing antibodies in vivo and in vitro. The two redone patents come to an end in 2023.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
